Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report

  • Timothy Owen
    Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada

    Division of Radiation Oncology, Department of Oncology, Queen's University, Kingston, Ontario, Canada
    Search for articles by this author
  • Andrea S. Fung
    Address for correspondence: Andrea Fung, MD, PhD, Medical Oncologist, Cancer Centre of Southeastern Ontario, Queen's University, Kingston, Ontario, Canada, K7L 5P9
    Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada

    Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, Ontario, Canada
    Search for articles by this author
Published:August 28, 2022DOI:

      Clinical Practice Points

      • Immune checkpoint inhibitor (ICI)-related myelitis is rare.
      • Majority of patients have persistent neurologic deficits despite first-line glucocorticoids suggesting that more aggressive immunosuppression (i.e. addition of another immunosuppressive agent to steroids) upfront might be warranted.
      • The current case report suggests that the combination of high dose steroids and IVIG might be a good combination for initial treatment of ICI-associated myelitis.
      • The interaction between radiation therapy and development of immune-related myelitis warrants further study.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mok TSK
        • Wu YL
        • Kudaba I
        • et al.
        • KEYNOTE-042 Investigators
        Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
        Lancet. 2019; 393: 1819-1830
        • Reck M
        • Rodríguez-Abreu D
        • Robinson AG
        • et al.
        • KEYNOTE-024 Investigators
        Pembrolizumab vs. chemotherapy for PD-L1-positive non-small-cell lung cancer.
        N Engl J Med. 2016; 375: 1823-1833
        • Reck M
        • Rodríguez-Abreu D
        • Robinson AG
        • et al.
        Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater.
        J Clin Oncol. 2019; 37: 537-546
        • Gandhi L
        • Rodríguez-Abreu D
        • Gadgeel S
        • et al.
        • KEYNOTE-189 Investigators
        Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.
        N Engl J Med. 2018; 378: 2078-2092
        • Gadgeel S
        • Rodríguez-Abreu D
        • Speranza G
        • et al.
        Updated analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.
        J Clin Oncol. 2020; 38: 1505-1517
        • Paz-Ares L
        • Luft A
        • Vicente D
        • et al.
        • KEYNOTE-407 Investigators
        Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.
        N Engl J Med. 2018; 379: 2040-2051
        • Paz-Ares L
        • Ciuleanu TE
        • Cobo M
        • et al.
        First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 198-211
        • Haanen JBAG
        • Carbonnel F
        • Robert C
        • et al.
        Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2017; 28: iv119-iv142
        • Brahmer JR
        • Lacchetti C
        • Schneider BJ
        • et al.
        • National Comprehensive Cancer Network
        Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline.
        J Clin Oncol. 2018; 36: 1714-1768
        • Schneider BJ
        • Naidoo J
        • Santomasso BD
        • et al.
        Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.
        J Clin Oncol. 2021; 39: 4073-4126
        • Brahmer JR
        • Abu-Sbeih H
        • Ascierto PA
        • et al.
        Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
        J Immunother Cancer. 2021; 9e002435
        • Cuzzubbo S
        • Javeri F
        • Tissier M
        • et al.
        Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
        Eur J Cancer. 2017; 73: 1-8
        • Kao JC
        • Liao B
        • Markovic SN
        • et al.
        Neurological complications associated with anti-programmed death 1 (PD-1) antibodies.
        JAMA Neurol. 2017; 74: 1216-1222
        • Spain L
        • Walls G
        • Julve M
        • et al.
        Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature.
        Ann Oncol. 2017; 28: 377-385
        • Johnson DB
        • Manouchehri A
        • Haugh AM
        • et al.
        Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
        J Immunother Cancer. 2019; 7: 134
        • Picca A
        • Berzero G
        • Bihan K
        • et al.
        Longitudinally extensive myelitis associated with immune checkpoint inhibitors.
        Neurol Neuroimmunol Neuroinflamm. 2021; 8: e967
        • Mohn N
        • Beutel G
        • Gutzmer R
        • Ivanyi P
        • Satzger I
        • Skripuletz T.
        Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy – review of the literature and future outlook.
        J Clin Med. 2019; 8: 1777
        • Vickers ML
        • Seidl B
        • Bigby K
        • et al.
        Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review.
        Case Rep Oncol Med. 2020; 2020: 8819296
        • Chang VA
        • Simpson DR
        • Daniels GA
        • Piccioni DE
        Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.
        J Immuno Ther Cancer. 2018; 6: 153
        • Charabi S
        • Engell-Noerregaard L
        • Nilsson AC
        • Stenör C.
        Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab.
        Front Neurol. 2021; 12655283
        • Abuzneid YS
        • Al-Janazreh H
        • Haif M
        • et al.
        Radiation induced delayed transverse myelitis and neurological deficit at tertiary care center.
        Ann Med Surg (Lond). 2021; 69 (Aug 18)102728
        • Goh C
        • Desmond PM
        • Phal PM.
        MRI in Transverse Myelitis.
        J Magnet Resonance Imag. 2014; 40: 1267-1279
        • Khan M
        • Ambady P
        • Kimbrough D
        • et al.
        Radiation-induced myelitis: initial and follow-up MRI and clinical features in patients at a single tertiary care institution during 20 years.
        AJNR Am J Neuroradiol. 2018; 39 (Aug): 1576-1581
        • Carausu M
        • Beddok A
        • Langer A
        • et al.
        Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
        J immunotherapy cancer. 2019; 7: 317
        • Marcus RB
        • Million RR.
        The incidence of myelitis after irradiation of the cervical spinal cord.
        IJROBP. 1990; 19: 3-8
        • McClelland III S
        • Cooper PH
        • Acheson AK
        • Ciporen JN
        • Jaboin JJ
        • Mitin T.
        Radiation recall myelitis following paclitaxel chemotherapy: The first reported case.
        Jour. of Radiosurg SBRT. 2018; 5: 331-334
        • Bünül A
        • Sarıkaya C
        • Öztürk O
        • Sarıkaya C.
        A brief case series of radiation associated myelopathy.
        Neurosciences. 2021; 26: 392-395
        • Masson I
        • Supiot S
        • Doutriaux-Dumoulin I
        • Thillays F.
        Report of a unique case of gemcitabine-induced radiation recall myelitis following spinal cord irradiation.
        BJR Case Rep. 2020; 6 (Apr 23)20190118